**The high 87.5% market-implied probability of “No” stems primarily from the strictly limited nature of Eli Lilly’s October 2024 Platform Technology Evaluation Agreement with Peptron, which grants only a non-exclusive internal R&D license for applying the SmartDepot microsphere platform to Lilly’s peptide candidates and explicitly excludes commercial rights.** This non-binding stage, terminable on 30 days’ notice, was extended through October 7, 2026, to allow additional in-vivo studies and scope expansion into CNS indications such as Alzheimer’s and Parkinson’s. However, ongoing joint research has produced only initial validation without any announced technology transfer, commercial licensing, or binding deal. Lilly’s parallel pursuit of Camurus’ FluidCrystal technology for long-acting incretins further underscores alternative delivery options. With the deadline weeks away and no reported shift from evaluation to commercialization, trader consensus reflects the substantial barriers to a qualifying agreement by the resolution date.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日13% 確率
$11,414 Vol.
$11,414 Vol.
2026/10/06
13% 確率
$11,414 Vol.
$11,414 Vol.
2026/10/06
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.**The high 87.5% market-implied probability of “No” stems primarily from the strictly limited nature of Eli Lilly’s October 2024 Platform Technology Evaluation Agreement with Peptron, which grants only a non-exclusive internal R&D license for applying the SmartDepot microsphere platform to Lilly’s peptide candidates and explicitly excludes commercial rights.**
This non-binding stage, terminable on 30 days’ notice, was extended through October 7, 2026, to allow additional in-vivo studies and scope expansion into CNS indications such as Alzheimer’s and Parkinson’s. However, ongoing joint research has produced only initial validation without any announced technology transfer, commercial licensing, or binding deal. Lilly’s parallel pursuit of Camurus’ FluidCrystal technology for long-acting incretins further underscores alternative delivery options. With the deadline weeks away and no reported shift from evaluation to commercialization, trader consensus reflects the substantial barriers to a qualifying agreement by the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
マーケット開始日： May 5, 2026, 8:02 PM ET
音量
$11,414終了日
2026/10/07マーケット開始日
May 5, 2026, 8:02 PM ETリゾルバー
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.**The high 87.5% market-implied probability of “No” stems primarily from the strictly limited nature of Eli Lilly’s October 2024 Platform Technology Evaluation Agreement with Peptron, which grants only a non-exclusive internal R&D license for applying the SmartDepot microsphere platform to Lilly’s peptide candidates and explicitly excludes commercial rights.**
This non-binding stage, terminable on 30 days’ notice, was extended through October 7, 2026, to allow additional in-vivo studies and scope expansion into CNS indications such as Alzheimer’s and Parkinson’s. However, ongoing joint research has produced only initial validation without any announced technology transfer, commercial licensing, or binding deal. Lilly’s parallel pursuit of Camurus’ FluidCrystal technology for long-acting incretins further underscores alternative delivery options. With the deadline weeks away and no reported shift from evaluation to commercialization, trader consensus reflects the substantial barriers to a qualifying agreement by the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$11,414終了日
2026/10/07マーケット開始日
May 5, 2026, 8:02 PM ETリゾルバー
0x65070BE91...**The high 87.5% market-implied probability of “No” stems primarily from the strictly limited nature of Eli Lilly’s October 2024 Platform Technology Evaluation Agreement with Peptron, which grants only a non-exclusive internal R&D license for applying the SmartDepot microsphere platform to Lilly’s peptide candidates and explicitly excludes commercial rights.** This non-binding stage, terminable on 30 days’ notice, was extended through October 7, 2026, to allow additional in-vivo studies and scope expansion into CNS indications such as Alzheimer’s and Parkinson’s. However, ongoing joint research has produced only initial validation without any announced technology transfer, commercial licensing, or binding deal. Lilly’s parallel pursuit of Camurus’ FluidCrystal technology for long-acting incretins further underscores alternative delivery options. With the deadline weeks away and no reported shift from evaluation to commercialization, trader consensus reflects the substantial barriers to a qualifying agreement by the resolution date.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問